Pharmaceutical Industry discussion, review, analysis, news and information.

"This U.S. approval closely follows the European approval of the IV formulation for Keppra® earlier this year. Keppra® is now the only newer anti-epileptic drug available in the U.S. and Europe with both oral and intravenous formulations."

Keppra®, developed and manufacrured by Belgian pharmaceutical firm, UCB Group (UCB), is indicated as an alternative for patients when oral administration is temporarily not feasible.

Source: UCB